Lupin has filed a second suit in the US against Ranbaxy Laboratories to prevent the country’s largest drugmaker from launching fenofibrate, a generic version of Lupin’s cholesterol lowering drug Antara in the US. The second lawsuit pertains to a new patent Lupin received in January from the US patent authority. It has been filed by a Swiss arm of the Mumbai-based drugmaker, Lupin Atlantis Holdings SA in the District Court for the Eastern District of Pennsylvania.
Lupin acquired rights to sell Antara in the world’s largest drug market from bankrupt American firm Oscient Pharmaceuticals in September 2009 for $38.61 million. Antara recorded net sales of $70 million in 2008. Lupin itself had challenged Oscient’s rights to sell Antara in the US before acquiring the drug. Fenofibrate products have a market of over $1.9 billion in the US. Antara has a small share of just around 5% and its sales are reportedly growing at around 20% a year.crackcrack
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: